Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content

Journal of Lipid Research

Volumn 40, Issue 2, 1999, Pages 202-212

  Khoo, Christina ^a   Campos, Hannia ^a   Judge, Helena ^a   Sacks, Frank M ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

apoB; apoC III; apoE; Atherosclerosis; Cholesterol; Estrogen; Lipoproteins; Oral contraceptives; Triglyceride

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CHOLESTEROL; CHOLESTEROL ESTER; DESOGESTREL PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORETHISTERONE; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MESTRANOL PLUS NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ANTIBODY; APOLIPOPROTEIN C; DIAGNOSTIC AGENT; ESTROGEN; LIPID; LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AFFINITY CHROMATOGRAPHY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; IMMUNOBLOTTING; LIPOPROTEIN METABOLISM; ORAL DRUG ADMINISTRATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; ULTRACENTRIFUGATION; BLOOD; COMPARATIVE STUDY; ELECTRON MICROSCOPY; HYPERTRIGLYCERIDEMIA; METABOLISM; METHODOLOGY; PARTICLE SIZE; ULTRASTRUCTURE;

ADULT; ANTIBODIES; APOLIPOPROTEIN C-III; APOLIPOPROTEINS B; APOLIPOPROTEINS C; APOLIPOPROTEINS E; CHOLESTEROL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; CHROMATOGRAPHY, AFFINITY; CONTRACEPTIVES, ORAL; ESTROGENS; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; LIPIDS; LIPOPROTEINS; MICROSCOPY, ELECTRON; PARTICLE SIZE; RESINS, SYNTHETIC;

EID: 0032910478     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Aalto-Setälä, K., P. H. Weinstock, C. L. Bisgaier, L. Wu, J. D. Smith, and J. L. Breslow. 1996. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice. J. Lipid Res. 37: 1802-1811.
2. Sehayek, E., and S. Eisenberg. 1991. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low-density lipoprotein receptor pathway. J. Biol. Chem. 266: 18259-18267.
3. Ebara, T., R. Ramakrishnan, G. Steiner, and N. S. Shachter. 1997. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J. Clin. Invest. 99: 2672-2681.
4. Ito, Y., N. Azrolan, A. O'Connell, A. Walsh, and J. L. Breslow. 1985. Hypertriglyceridemia as a result of human apoCIII gene expression in transgenic mice. Science. 249: 790-793.
5. Malmendier, C. L., J. Lontie, C. Delcroix, D. Y. Dubois, T. Magot. and L. De Roy. 1989. Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Atherosclerosis. 77: 139-149.
6. Ginsberg, H. N. , N. Le, I. J. Goldberg, J. C. Gibson, A. Rubinstein, P. Wang-Iverson, R. Norum, and W. V. Brown. 1986. Apolipoprotein B metabolism in subjects with deficiency of apolipoprotein CIII and AI. J. Clin. Invest. 78: 1287-1295.
7. Maeda, N., H. Li, D. Lee, P. Oliver, S. H. Quarfordt, and J. Osada. 1994. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J. Biol. Chem. 269: 23610-23616.
8. Dergunov, A. D., and M. Rosseneu. 1994. The significance of apolipoprotein E structure to the metabolism of plasma triglyceriderich lipoproteins. Biol. Chem. Hoppe-Seyler. 375: 485-495.
9. Friedman, G., D. Gavish, D. Vogel, and S. Eisenberg. 1990. Cellular metabolism of human intermediate-density lipoprotein (IDL). Biochim. Biophys. Acta. 1044: 118-126.
10. Bradley, W. A., and S. H. Gianturco. 1986. ApoE is necessary and sufficient for the binding of large triglyceride-rich lipoproteins to the LDL receptor; apoB is unnecessary. J. Lipid Res. 27: 40-48.
11. Schaefer, E. J., R. E. Gregg, G. Ghiselli, T. M. Forte, J. M. Ordovas, L. A. Zech, and H. B. Brewer. 1986. Familial apolipoprotein E deficiency. J. Clin. Invest. 78: 1206-1219.
12. Zhang, S. H., R. L. Reddick, B. Burkey, and N. Maeda. 1994. Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. J Clin. Invest. 94: 937-945.
13. Ehnholm, C., R. W. Mahlev, D. A. Chappell, K. H. Weisgraber, E. Ludwig, and J. L. Witztum. 1984. Role of apolipoprotein E in the lipolytic conversion of beta VLDI. to LDL in type III hyperlipoproteinemia. Proc. Natl. Acad. Sci. USA. 81: 5566-5570.
14. Luc, G., C. Fievet, D. Arveiler, A. E. Evans, J. Bard, F. Cambien, J. Fruchart, and P. Ducimetiere. 1996. Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. J. Lipid Res. 37: 508-517.
15. Chivot, L., F. Mainard, E. Bigot, J. M. Bard, J. L. Auget, Y. Madec, and J. C. Fruchart. 1990. Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins CIII and E. Atherosclerosis. 82: 205-211.
16. Alaupovic, P., H. N. Hodis, C. Knight-Gibson, W. J. Mack, L. La-Bree, L. Cashin-Hemphill, C. N. Corder, D. M. Kramsch, and D. H. Blankenhorn. 1994. Effects of lovastatin on apoA- and apoB-containing lipoprotein families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS). Arterioscler. Thromb. 14: 1906-1914.
17. Blankenhorn, D. H., P. Alaupovic, E. Wickham, H. P. Chin, and S. P. Azen. 1990. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Circulation. 81: 470-476.
18. Syvänne, M., M. Rosseneu, C. Labeur, H. Hilden, and M. Taskinen. 1994. Enrichment with apolipoprotein Y. characterizes postprandial TG-rich lipoproteins in patients with non-insulin-dependent diabetes mellitus and coronary artery disease: a preliminary report. Atherosclerosis. 105: 25-34.
19. Genest, J. J., Jr., J. M. Bard, J. Fruchart, J. M. Ordovas, P. F. W. Wilson, and E. J. Schaefer. 1991. Plasma apolipoproiein AI, AII, B, E and CIII-containing particles in men with premature coronary artery disease. Atherosclerosis. 90: 149-157.
20. Cohn, J. S., M. Tremblay, M. Amiot, D. Boulhillier, M. Roy, J. J. Genest, Jr., and J. Davignon. 1996. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. Arterioscler. Thromb. Vasc. Biol. 16: 149-159.
21. Gianturco, S. H., A. H. Lin, S. C. Hwang, J. Young, S. A. Brown, D. P. Via, and W. A. Bradley. 1988. Distinct murine macrophage receptor pathway for human triglyceride-rich lipoproteins. J. Clin. Invest. 82: 1633-1643.
22. Getz, G. S., T. Mazzone, P. Soltys, and S. R. Bates. 1988. Atherosclerosis and apoprotein E. Arch. Pathol. Lab. Med. 112: 1048-1055.
23. The Lipid Research Clinics Program Epidemiology Committee. 1979. Plasma lipid distribution in selected North American populations: The Lipid Research Clinics Program Prevalence Study. Circulation. 60: 427-439.
24. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34: 1345-1353.
25. Alaupovic, P. 1991. Apolipoprotein composition as the basis for classifying plasma lipoproteins. Characterization of apoA- and apoB-containing lipoprotein families. Prog. Lipid Res. 30: 105-138.
26. Kowal, R. C., J. Herz, K. H. Weisgraber, R. W. Mahley, M. S. Brown, and J. L. Goldstein. 1990. Opposing effects of apolipoprotein E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J. Biol. Chem. 265: 10771-10779.
27. Li, Z., J. R. McNamara, J. Fruchart, G. Luc, J. M. Bard, J. M. Ordovas, P. W. F. Wilson, and E. J. Schaefer. 1996. Effects of gender and menopausal status on plasma lipoprotein species and particle sizes. J. Lipid Res. 37: 1886-1896.
28. Stampfer, M. J., W. C. Willett, G. A. Colditz, F. K. Speizer, and C. H. Hennekens. 1990. Past use of oral contraceptives and cardiovascular disease: a meta-analysis in the context of Nurses' Health Study. Am. J. Obstet. Gynecol. 163: 285-291.
29. Schaefer, E. J., D. M. Foster, L. A. Zech, F. T. Lindgren, H. B. Brewer, Jr., and R. I. Levy. 1983. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J. Clin. Endocrinot. Metab. 57: 262-267.
30. Wahl, P., C. Walden, R. Knopp, J. Hoover, R. Wallace, G. Heiss, and B. Rifkind. 1983. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N. Engl. J. Med. 308: 862-867.
31. Walsh, B. W., and F. M. Sacks. 1993. Effects of low dose oral contraceptives on very low density and low density lipoprotein metabolism. J. Clin. Invest. 91: 2126-2132.
32. Godsland, I. F., D. Crook, R. Simpson, T. Proudler, C. Felton, B. Lees, V. Anyaoku, M. Devenport, and V. Wynn. 1990. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N. Engl. J. Med. 323: 1375-1381.
33. Campos, H., B. W. Walsh, H. Judge, and F. M. Sacks. 1997. Effect of estrogen on very low density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women. J. Clin. Endocrinol. Metab. 82: 3955-3963.
34. Sacks, F. M., H. Campos, H. Judge, and B. W. Walsh. 1997. Estrogen treatment and human lipoprotein metabolism. In Hormonal, Metabolic, and Cellular Influences on Cardiovascular Disease in Women. T. M. Forte, editor. Futura Publishing Company, Inc., Armonk, NY. 229-246.
35. Walsh, B. W., I. Schiff, B. Rosner, L. Grenberg, V. Ravnikar, and F. M. Sacks. 1991. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N. Engl. J. Med. 325: 1196-1204.